<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02697838</url>
  </required_header>
  <id_info>
    <org_study_id>AHEAD-G323</org_study_id>
    <nct_id>NCT02697838</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer</brief_title>
  <official_title>Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujian Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fujian Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single arm study: Apatinib plus paclitaxel as the reverses treatment in advanced gastric
      cancer which paclitaxel-resistant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial investigated the efficacy and safety of apatinib plus paclitaxel, as a treatment
      option for patients with advanced gastric cancer which paclitaxel-resistant.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 1, 2016</start_date>
  <completion_date type="Anticipated">October 31, 2018</completion_date>
  <primary_completion_date type="Actual">March 31, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease control rate(DCR)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Malignant Neoplasm of Stomach Stage II</condition>
  <arm_group>
    <arm_group_label>Experimental: Apatinib plus chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Apatinib (850 mg qd p.o.) until disease progression or intolerable toxicity or refused by the patients.</description>
    <arm_group_label>Experimental: Apatinib plus chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel-based chemotherapeutic regimens</intervention_name>
    <description>Paclitaxel-based chemotherapeutic regimens including:
The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
The PF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
Paclitaxel 80mg/m2 d1，d8，d15，repeating the cycle every 28 days
other paclitaxel-based regimens</description>
    <arm_group_label>Experimental: Apatinib plus chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: more than 18 years old;

          2. Histologically confirmed advanced or metastatic adenocarcinoma of gastric cancer(AGC)
             , including adenocarcinoma of the gastroesophageal junction;

          3. At least one measurable and evaluable disease based on response evaluation criteria in
             solid tumors (RECIST v1.1);

          4. The patient with Prior Paclitaxel-Resistant;

          5. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-2;

          6. An expected survival of ≥ 3 months;

          7. Duration from the last therapy is more than 6 weeks for nitroso or mitomycin, More
             than 4 weeks for other cytotoxic agents, operation or radiotherapy;

          8. Major organ function has to meet the following criteria; (1) For results of blood
             routine test:

               1. Hemoglobin (HB) ≥ 80g / L,

               2. ANC ≥ 1.5 × 109 / L,

               3. PLT ≥ 75 × 109 / L, (2) For results of biochemical tests:

               1. BLT ≤ 1.25 times the upper limit of normal (ULN),

               2. ALT and AST ≤ 2.5 × ULN, liver metastases, if any, the ALT and AST≤ 5 × ULN,

               3. Serum Cr≤1ULN, Endogenous creatinine clearance rate ＞50ml/min;

          9. Pregnancy test (serum or urine) has to be performed for woman of childbearing age
             within 7 days before enrolment and the test result must be negative. They shall take
             appropriate methods for contraception during the study until the 8th week post the
             last administration of study drug. For men, (previous surgical sterilization
             accepted), shall agree to take appropriate methods of contraception during the study
             until the 8th week post the last administration of study drug;

         10. Patient has to voluntarily join the study and sign the Informed Consent Form for the
             study.

        Exclusion Criteria:

          1. History of other malignancies except cured basal cell carcinoma of skin and carcinoma
             insitu of uterine cervix;

          2. Confirmed that apatinib and/or its accessories allergy;

          3. Subjects with poor-controlled arterial hypertension (systolic blood pressure&gt; 140 mmHg
             and diastolic blood pressure &gt; 90 mm Hg) despite standard medical management;

          4. Serious cardiovascular disease: Ⅱ-level myocardial ischemia or myocardial infarction,
             arrhythmia (including QT interval prolongation, for man ≥ 450 ms, for woman ≥ 470 ms);
             III ~ IV level cardiac function insufficiency, or echocardiography showed that left
             ventricular ejection fraction (LVEF &lt; 50%);

          5. Patients with positive urinary protein (urine protein detection of 2 or more, or 24
             hour urine protein &gt;1.0g);

          6. Factors that could have an effect on oral medication (such as inability to swallow,
             chronic diarrhea and intestinal obstruction);

          7. Subjects with high gastrointestinal bleeding risk, including the following conditions:
             local active ulcer lesions with positive fecal occult blood test (++); history of
             black stool, or vomiting blood in the past 2 months;unresected primary lesion in
             stomach with positive fecal occult blood test (+), ulcerated gastric carcinoma with
             massive alimentary tract bleeding risk judged by PIs based on gastric endoscopy
             result;

          8. Abnormal Coagulation (INR&gt;1.5、APTT&gt;1.5 UNL), with tendency of bleed;

          9. With psychotropic drug abuse history and can't get rid or with mental disorder
             patients;

         10. Less than 4 weeks from the last clinical trial;

         11. According to the researcher's judgment, with other serious diseases which harm to
             patient safety or affect patients complete the study;

         12. Evidence of central nervous system(CNS) metastasis;

         13. Pregnant or lactating women;

         14. Other conditions regimented at investigators' discretion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rongbo Lin</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350014</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>February 25, 2016</study_first_submitted>
  <study_first_submitted_qc>February 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2016</study_first_posted>
  <last_update_submitted>October 13, 2018</last_update_submitted>
  <last_update_submitted_qc>October 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

